-
Product Insights
Jasper Generating Plant
Jasper Generating Plant is a thermal project located in South Carolina, United States. The project is owned by Dominion Energy South Carolina Inc. The project came online in 2004. Empower your strategies with our Jasper Generating Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
Jasper Solar PV park
Jasper Solar PV park is a solar PV project located in Northern Cape, South Africa. The project is owned by Alphabet Inc; Intikon Energy; Kensani Capital; Public Investment Corp Ltd; SolarReserve LLC and was developed by Intikon Energy; Kensani Capital; SolarReserve LLC. The project came online in 2014. Empower your strategies with our Jasper Solar PV park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be...
-
Product Insights
OPDE Jasper Solar PV Park
OPDE Jasper Solar PV Park is a solar PV project located in Texas, United States. The project is owned and being developed by OPDE Holding SA. The project is expected to come online in 2024. Empower your strategies with our OPDE Jasper Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Myelodysplastic Syndrome Drug Details: Briquilimab (AMG-191) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Chronic Urticaria Or Hives Drug Details: Briquilimab (AMG-191)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Fanconi Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Fanconi Anemia - Drugs In Development, 2023’, provides an overview of the Fanconi Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fanconi Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Granulomatous Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Granulomatous Disease - Drugs In Development, 2023’, provides an overview of the Chronic Granulomatous Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Granulomatous Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...